Lupin Limited's Nagpur, India, injectable facility passed a US FDA inspection without 483 observations.

Lupin Limited's Nagpur, India, Injectable facility passed a US FDA inspection without any 483 observations, indicating adherence to high-quality standards. This follows a pre-approval inspection in May with six 483 observations at a New Jersey facility. Lupin, the 3rd largest US pharmaceutical company by prescriptions, has 15 manufacturing sites and over 20,000 professionals globally.